Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

G. Richardson, Paul; Jacobus, Susanna; Weller, Edie; Hassoun, Hani; Lonial, Sagar; Raje, Noopur; Medvedova, Eva; L. McCarthy, Philip; N. Libby, Edward; M. Voorhees, Peter; Z. Orlowski, Robert; D. Anderson, Larry; A. Zonder, Jeffrey; P. Milner, Carter; Gasparetto, Cristina; Agha, Mounzer; Khan, Abdullah; D. Hurd, David; Gowin, Krisstina; T. Kamble, Rammurti; Jagannath, Sundar; Nathwani, Nitya; Alsina, Melissa; F. Cornell, Robert; Hashmi, Hamza; Campagnaro, Erica; C. Andreescu, Astrid; Gentile, Teresa; Liedtke, Michaela; Godby, Kelly; D. Cohen, Adam; H. Openshaw, Thomas; C. Pasquini, Marcelo; Giralt, Sergio; L. Kaufman, Jonathan; J. Yee, Andrew; C. Scott, Emma; Torka, Pallawi; Foley, Amy; Fulciniti, Mariateresa; Hebert, Kyle; Samur, Mehmet; Masone, Kelly; E. Maglio, Michelle; A. Zeytoonjian, Andrea; Nadeem, Omar; Schlossman, Robert; P. Laubach, Jacob; E. Paba‐Prada, Claudia; M. Ghobrial, Irene; Perrot, Aurore; Moreau, Philippe; Avet‐Loiseau, Hervé; Attal, Michel; C. Anderson, Kenneth; C. Munshi, Nikhil

doi:10.1056/nejmoa2204925

Public

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Published in New England Journal of Medicine • Jun 5, 2022

Authors:

Paul G. Richardson

Susanna Jacobus

Edie Weller

Abstract

BACKGROUND: In patients with newly diagnosed multiple myeloma, the effect of adding autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and dexamethasone [RVD]), followed by lenalidomide maintenance therapy until disease progression, is unknown. METHODS: In this...

Subject

Medicine

Multiple myeloma

Lenalidomide

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!